Evidence map›Paper›PMID 34258749›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

FRET-Based Screening Identifies p38 MAPK and PKC Inhibition as Targets for Prevention of Seeded α-Synuclein Aggregation.

Alexander Svanbergsson, Fredrik Ek, Isak Martinsson, Jordi Rodo, Di Liu, Edoardo Brandi, Caroline Haikal, Laura Torres-Garcia, Wen Li, Gunnar Gouras and 3 more

Abstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Monitoring α-synuclein aggregation.Neurobiology of disease · 2023
    Review
  4. Article
  5. The Bacterial Amyloids Phenol Soluble Modulins fromInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander SvanbergssonDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-4435-7653
Fredrik EkChemical Biology & Therapeutics, Department of Experimental Medicinal Science, Lund University, Lund, Sweden.
Isak MartinssonExperimental Dementia Research, Department of Experimental Medicine, Lund University, Lund, Sweden.
Jordi RodoDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Di LiuDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Edoardo BrandiDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Caroline HaikalDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Laura Torres-GarciaDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Wen LiDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden.
Gunnar GourasExperimental Dementia Research, Department of Experimental Medicine, Lund University, Lund, Sweden.
Roger OlssonChemical Biology & Therapeutics, Department of Experimental Medicinal Science, Lund University, Lund, Sweden.
Tomas BjörklundMolecular Neuromodulation, Department of Experimental Medicine, Lund University, Lund, Sweden.
Jia-Yi LiDepartment of Experimental Medicine, Neural Plasticity and Repair, Lund University, Lund, Sweden. Jia-yi.li@med.lu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggregation of α-synuclein is associated with neurodegeneration and a hallmark pathology in synucleinopathies. These aggregates are thought to function as prion-like particles where the conformation of misfolded α-synuclein determines the traits of the induced pathology, similar to prion diseases. Still, little is known about the molecular targets facilitating the conformation-specific biological effects, but their identification could form the basis for new therapeutic interventions. High-throughput screening of annotated compound libraries could facilitate mechanistic investigation by identifying targets with impact on α-synuclein aggregation. To this end, we developed a FRET-based cellular reporter in HEK293T cells, with sensitivity down to 6.5 nM α-synuclein seeds. Using this model system, we identified GF109203X, SB202190, and SB203580 as inhibitors capable of preventing induction of α-synuclein aggregation via inhibition of p38 MAPK and PKC, respectively. We further investigated the mechanisms underlying the protective effects and found alterations in the endo-lysosomal system to be likely candidates of the protection. We found the changes did not stem from a reduction in uptake but rather alteration of lysosomal abundance and degradative capacity. Our findings highlight the value high-throughput screening brings to the mechanistic investigation of α-synuclein aggregation while simultaneously identifying novel therapeutic compounds.

Indexed as

alpha-SynucleinCells, CulturedDrug Delivery SystemsEnzyme InhibitorsFluorescence Resonance Energy TransferHEK293 CellsHumansImidazolesp38 Mitogen-Activated Protein KinasesProtein Aggregation, PathologicalProtein Kinase CProteomePyridines4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazolealpha-SynucleinEnzyme InhibitorsImidazolesp38 Mitogen-Activated Protein KinasesProtein Kinase CProteomePyridinesSNCA protein, humanEndosomeFRETHigh-throughput screeningKinaseLysosomeProteomicsα-Synuclein

Identifiers

PMID34258749
PMCPMC8609038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.